Clinical Challenges

Prechemotherapy Cardiac Assessment

Susan Moore

cardiotoxicity
ONF 2009, 36(5), 503-506. DOI: 10.1188/09.ONF.503-506

Jump to a section

    References

    Altena, R., Perik, P.J., van Veldhuisen, D.J., de Vries, E.G.E., & Gietema, J.A. (2009). Cardiovascular toxicity caused by cancer treatment: Strategies for early detection. Lancet Oncology, 10(4), 391-399.
    American Nurses Association. (2005). Code of ethics for nurses. Retrieved May 13, 2009, from http://www.nursingworld.org/MainMenuCategories/EthicsStandards/CodeofEthics.aspx
    Carver, J.R., Shapiro, C.L., Ng, A., Jacobs, L., Schwartz, C., Virgo, K.S., et al. (2007). American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: Cardiac and pulmonary late effects. Journal of Clinical Oncology, 25(25), 3991-4008.
    Ganz, P.A., Hussey, M.A., Moinpour, C.M., Unger, J.M., Hutchins, L.F., Dakhil, S.R., et al. (2008). Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group Protocol S8897. Journal of Clinical Oncology, 26(8), 1223-1230.
    Gianni, L., Baselga, J., Eiermann, W., Guillem Porta, V., Semiglazov, V., Lluch, A., et al. (2005). Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research, 11(24), 8715-8721.
    Gianni, L., Salvatorelli, E., & Minotti, G. (2007). Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes. Cardiovascular Toxicology, 7(2), 67-71.
    Giordano, S.H., Kuo, Y.F., Freeman, J.L., Bucholz, T.A., Hortobagyi, G.N., & Goodwin, J.S. (2005). Risk of cardiac death after adjuvant radiotherapy for breast cancer. Journal of the National Cancer Institute, 97(6), 419-424.
    Hall, J.K., & Hall, D. (2001). Elements of nursing negligence. In M.E. O'Keefe (Ed.), Nursing practice and the law: Avoiding malpractice and other legal risks (pp. 140-141). Philadelphia: F.A. Davis.
    Hershman, D.L., & Shao, T. (2009). Anthracycline toxicity after breast cancer treatment. Oncology, 23(3), 227-239.
    Hunt, S.A., Abraham, W.T., Chin, M.H., Feldman, A.M., Francis, G.S., Ganiats, T.G., et al. (2005). ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 112(12), E154-E235.
    Kaszyk, L.K. (1986). Cardiac toxicity associated with cancer therapy. Oncology Nursing Forum, 13(4), 81-88.
    Loerzel, V.W., & Dow, K.H. (2003). Cardiac toxicity related to cancer treatment. Clinical Journal of Oncology Nursing, 7(5), 557-562.
    Mitani, I., Jain, D., Joska, T.M., Burtness, B., & Zaret, B.L. (2003). Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. Journal of Nuclear Cardiology, 10(2), 132-139.
    National Comprehensive Cancer Network. (2009). NCCN Clinical Practice Guidelines in Oncology™: Breast cancer [v.1.09]. Retrieved May 11, 2009, from http://nccn.org/professionals/physician_gls/PDF/breast.pdf
    Pfizer, Inc. (2006). Doxorubicin hydrochloride for injection [Prescribing information]. Retrieved May 12, 2009, from http://media.pfizer.com/files/products/uspi_adriamycin.pdf
    Rosenthal, D.S., & Braunwald, E. (2001). Cardiac effects of radiation therapy and chemotherapy. In E. Braunwald (Ed.), Heart disease: A textbook of cardiovascular medicine (pp. 1746-1751). Philadelphia: W.B. Saunders.
    Sabel, M.S., Levine, E.G., Hurd, T., Schwartz, G.N., Zielinski, R., Hohn, D., et al. (2001). Is MUGA scan necessary in patients with low-risk breast cancer before doxorubicin-based adjuvant therapy? American Journal of Clinical Oncology, 24(4), 425-428.
    Safra, T. (2007). Chemotherapeutics and cardiac toxicity: Treatment considerations and management strategies. Community Oncology, 4(9), 540-548.
    Schulmeister, L. (2009). From the editors. Retrieved May 7, 2009, from http://onsopcontent.ons.org/Publications/SIGNewsletters/chemo/chemo20.1.html
    Shan, K., Lincoff, M., & Young, J.B. (1996). Anthracycline-induced cardiotoxicity. Annals of Internal Medicine, 125(1), 47-58.
    Shelton, B.K. (2009). Cardiovascular toxicity. In M. Polovich, J.M. Whitford, & M. Olsen (Eds.), Chemotherapy and biotherapy guidelines and recommendations for practice. (3rd ed.). Pittsburgh, PA: Oncology Nursing Society.
    Teytelman, Y. (2002). Effective nursing documentation and communication. Seminars in Oncology Nursing, 18(2), 121-127.
    Von Hoff, D.D., Layard, M.W., Basa, P., Davis, J.L., Von Hoff, A.L., Rosenzweig, M., et al. (1979). Risk factors for doxorubicininduced congestive heart failure. Annals of Internal Medicine, 91(5), 710-717.
    Youssef, G., & Links, M. (2005). The prevention and management of cardiovascular complications of chemotherapy in patients with cancer. American Journal of Cardiovascular Drugs, 5(4), 233-243.
    Altena, R., Perik, P.J., van Veldhuisen, D.J., de Vries, E.G.E., & Gietema, J.A. (2009). Cardiovascular toxicity caused by cancer treatment: Strategies for early detection. Lancet Oncology, 10(4), 391-399.
    American Nurses Association. (2005). Code of ethics for nurses. Retrieved May 13, 2009, from http://www.nursingworld.org/MainMenuCategoriesEthicsStandards/CodeofEthics.aspx
    Ganz, P.A., Hussey, M.A., Moinpour, C.M., Unger, J.M., Hutchins, L.F., Dakhil, S.R., et al. (2008). Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group Protocol S8897. Journal of Clinical Oncology, 26(8), 1223-1230.
    Gianni, L., Salvatorelli, E., & Minotti, G. (2007). Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes. Cardiovascular Toxicology, 7(2), 67-71.
    Hall, J.K., & Hall, D. (2001). Elements of nursing negligence. In M.E. O'Keefe (Ed.), Nursing practice and the law: Avoiding malpractice and other legal risks (pp. 140-141). Philadelphia: F.A. Davis.
    Hershman, D.L., & Shao, T. (2009). Anthracycline toxicity after breast cancer treatment. Oncology, 23(3), 227-239.
    Hunt, S.A., Abraham, W.T., Chin, M.H., Feldman, A.M., Francis, G.S., Ganiats, T.G., et al. (2005). ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 112(12), E154-E235.
    Rosenthal, D.S., & Braunwald, E. (2001). Cardiac effects of radiation therapy and chemotherapy. In E. Braunwald (Ed.), Heart disease: A textbook of cardiovascular medicine (pp. 1746-1751). Philadelphia: W.B. Saunders.
    Safra, T. (2007). Chemotherapeutics and cardiac toxicity: Treatment considerations and management strategies. Community Oncology, 4(9), 540-548.
    Shan, K., Lincoff, M., & Young, J.B. (1996). Anthracycline-induced cardiotoxicity. Annals of Internal Medicine, 125(1), 47-58.
    Youssef, G., & Links, M. (2005). The prevention and management of cardiovascular complications of chemotherapy in patients with cancer. American Journal of Cardiovascular Drugs, 5(4), 233-243.